VCYT

SOUTH SAN FRANCISCO, Calif., July 09, 2026--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/wwu2pyd7. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations. About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709945913/en/ Contacts Investors Kelly [email protected] Media Molly [email protected] +1-650-351-8780

A month has gone by since the last earnings report for Veracyte (VCYT). Shares have added about 18.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Veracyte due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers. Veracyte, Inc. (VCYT) delivered first-quarter 2026 adjusted earnings of 52 cents per share, up 67.7% from the year-ago period. The bottom line beat the Zacks Consensus Estimate by 52.9%. The company’s GAAP earnings per share were 35 cents compared with the year-ago period’s 9 cents per share. Revenues increased 21.5% year over year to $ 139.1 million, which outpaced the Zacks Consensus Estimate by 6.6%. Veracyte raised its 2026 total revenue guidance to $582-$592 million or 13-14% growth (up from $570-$582 million or 10-13%). The Zacks Consensus Estimate for revenues is currently pegged at $580.3 million, implying 12.2% year-over-year growth. Additionally, Veracyte raised its adjusted EBITDA margin guidance to greater than 26%, up from its prior expectation of approximately 25%. It turns out, estimates review flatlined during the past month. At this time, Veracyte has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Veracyte has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Veracyte belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Edwards Lifesciences (EW), has gained 3.4% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026. Edwards Lifesciences reported revenues of $1.65 billion in the last reported quarter, representing a year-over-year change of +16.7%. EPS of $0.78 for the same period compares with $0.64 a year ago. For the current quarter, Edwards Lifesciences is expected to post earnings of $0.73 per share, indicating a change of +9% from the year-ago q...

Additional Data from ENZAMET Study Show How Decipher Can Help Metastatic Prostate Cancer Patients Avoid Unnecessary Treatment and Enable More Personalized Care SOUTH SAN FRANCISCO, Calif., May 21, 2026--(BUSINESS WIRE)--Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 – June 2. The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer. The OPTIMA study is a prospective, randomized trial led by University College London (UCL) and supported by the National Institute for Health Research (NIHR). The study enrolled more than 4,400 patients and was designed to address a key clinical question: which patients would benefit from chemotherapy, and which may be able to safely avoid it, and its long-term toxicities. The study results demonstrating how the Prosigna test can guide adjuvant chemotherapy decisions in patients with high-risk breast cancer will be presented by Dr. Rob Stein of UCL and OPTIMA Trial Chief Investigator, on Saturday, May 30 during the breast cancer session. "The OPTIMA trial results represent a major milestone in precision breast oncology and will provide Level 1A evidence supporting Prosigna-guided treatment decisions," said Kelly Marcom, M.D., Veracyte’s medical director, Breast Cancer. "These findings have the potential to transform how clinicians treat a large population of patients with breast cancer, helping them to personalize their patient’s treatment choices using the genomic insights that the Prosigna test provides." The ENZAMET trial is an international, prospective, randomized study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Dr. Christopher Sweeney of South Australian Immunogenomics Cancer Institute, Adelaide University, will present data on Saturday, May 30 during the Genitourinary Cancer session on Decipher Prostate’s ability to predict treatment benefit with the chemotherapy docetaxel in metastatic, hormone-sensitive prostate cancer. The independent analysis evaluated how the Deciphe...

When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s (NASDAQ:VCYT) stock has recently. We have done some analysis, and we found several positive factors beyond the profit numbers. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. For anyone who wants to understand Veracyte's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by US$12m due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Veracyte to produce a higher profit next year, all else being equal. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Unusual items (expenses) detracted from Veracyte's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Veracyte's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Obviously, we love to consider the historical data to inform our opinion of a company. But it can be really valuable to consider what other analysts are forecasting. At Simply Wall St, we have analyst estimates which you can view by clicking here. Today we've zoomed in on a single data point to better understand the nature of Veracyte's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feed...

Veracyte, Inc. (NASDAQ:VCYT) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. The company beat forecasts, with revenue of US$139m, some 6.7% above estimates, and statutory earnings per share (EPS) coming in at US$0.35, 150% ahead of expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Taking into account the latest results, the consensus forecast from Veracyte's twelve analysts is for revenues of US$583.1m in 2026. This reflects a modest 7.6% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to shrink 2.3% to US$1.08 in the same period. Before this earnings report, the analysts had been forecasting revenues of US$576.6m and earnings per share (EPS) of US$0.90 in 2026. Although the revenue estimates have not really changed, we can see there's been a very substantial lift in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result. See our latest analysis for Veracyte The consensus price target was unchanged at US$47.10, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Veracyte at US$53.00 per share, while the most bearish prices it at US$37.00. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Veracyte's revenue growth is expected to slow, with the forecast 10% annualised growth rate until the end of...

Veracyte (VCYT) reported Q1 non-GAAP net income late Tuesday of $0.52 per diluted share, up from $0.

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Veracyte Inc. (VCYT) on Tuesday reported first-quarter earnings of $28.7 million. The South San Francisco, California-based company said it had net income of 35 cents per share. Earnings, adjusted for one-time gains and costs, came to 52 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 34 cents per share. The molecular diagnostic company posted revenue of $139.1 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $130.5 million. Veracyte expects full-year revenue in the range of $582 million to $592 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VCYT at https://www.zacks.com/ap/VCYT

Grew total revenue to $139.1 million and testing revenue to $135.1 million, representing increases of 21% and 26% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 05, 2026--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2026. "We had a strong start to the year, with Decipher and Afirma volume growth surpassing expectations and exceeding our profitability targets," said Marc Stapley, Veracyte’s CEO. "Our growing clinical evidence continues to set us apart, and this quarter strengthened it even further. We believe we are approaching an inflection point with the upcoming launches of Prosigna LDT and TrueMRD, two of the most significant new products in our history, creating meaningful opportunities for market expansion in Breast, Bladder and other cancers, alongside continued growth in our Prostate and Thyroid businesses." Key Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period in 2025: Increased total revenue by 21% to $139.1 million and testing revenue by 26% to $135.1 million, driven by Decipher growth of 30% to $86.5 million and Afirma growth of 21% to $46.4 million. Increased total volume by 17% to 47,615 tests and testing volume by 19% to 45,248 tests, driven by Decipher growth of 24% to approximately 28,000 tests and Afirma growth of 12% to approximately 17,200 tests. Recorded GAAP net income of $28.7 million, or 20.6% of revenue, and delivered adjusted EBITDA of $42.8 million, or 30.8% of revenue. Generated $35.2 million of cash from operations to end the quarter with $439.1 million of cash, cash equivalents, and short-term investments as of March 31, 2026. Key Business Highlights Advanced the evidence pipeline for Decipher with enrollment completed for GUIDANCE and G-MAJOR phase III trials. Announced data published in European Urology Oncology showing Decipher’s ability to stratify risk among patients undergoing active surveillance. Announced more than 15 studies featuring Decipher Prostate and Decipher Bladder will be presented at the AUA Annual Meeting next week, including the expanding impact of Decipher Prostate in studies using real-world data. Strengthened the leadership team with the appointments of Kevin Haas as Chief Developm...

Veracyte (VCYT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +52.94%. A quarter ago, it was expected that this molecular diagnostic company would post earnings of $0.41 per share when it actually produced earnings of $0.53, delivering a surprise of +29.27%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Veracyte, which belongs to the Zacks Medical - Instruments industry, posted revenues of $139.07 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 6.60%. This compares to year-ago revenues of $114.47 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Veracyte shares have lost about 20.6% since the beginning of the year versus the S&P 500's gain of 5.2%. While Veracyte has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Veracyte was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy...

Performance was driven by a multi-year transformation into a scalable, diversified company, achieving a 30.8% adjusted EBITDA margin that significantly exceeds the long-term 25% target. Decipher volume grew 24% year-over-year, fueled by nearly 30% growth in high-risk categories such as metastatic disease and biochemical recurrence as the market shifts toward biology-driven treatment. The transition to the V2 transcriptome workflow for Afirma improved the no-result rate, contributing approximately 400 basis points to volume growth by providing actionable results for historically challenging samples. Management attributes Decipher's sustained momentum to its unique position as the only gene expression test supported by high-quality clinical evidence and NCCN guidelines across the full spectrum of prostate cancer risk. The company is leveraging its Decipher GRID database of over 350,000 digitized images to integrate digital pathology and AI-powered analysis as complementary tools to molecular profiling. Operational efficiencies and a favorable business mix drove non-GAAP gross margin expansion of 350 basis points year-over-year to 75.7%. Management anticipates an inflection point with the mid-year launches of Prosigna LDT and TruMRD, which are expected to expand the addressable market and extend the platform into new clinical settings. The 2026 revenue guidance was raised to $582 million–$592 million, assuming high single-digit to low double-digit growth for Afirma and approximately 20% growth for Decipher. Guidance assumes a 2% to 3% full-year volume benefit from Afirma's improved no-result rate, accounting for potential summer heat-related RNA degradation and tougher year-over-year comparisons. The Prosigna LDT launch strategy is contingent on the OPTIMA Phase 3 trial results at ASCO; positive data on the primary non-inferiority endpoint is considered essential for Level 1A evidence and guideline inclusion. TruMRD's initial launch in muscle-invasive bladder cancer (MIBC) will focus on recurrence monitoring, leveraging established commercial channels where 70% of MIBC patients are currently seen. The company reclassified certain IT expenses from G&A to R&D to better align software development and project management costs with product development objectives. First quarter results included $4 million in prior-period collections (PPCs), which added approximately...

Veracyte posted Q1 revenue of $139.1 million, up 21% year‑over‑year, with GAAP net income of $28.7 million and adjusted EBITDA of $42.8 million (30.8% of revenue), and it raised full‑year 2026 revenue guidance to $582–$592M with adjusted EBITDA >26%. Decipher and Afirma drove volume growth (Decipher ~28,000 tests, +24% YoY; Afirma ~17,200, +12%), with Decipher showing ~30% growth in high‑risk prostate categories and advancing multiple phase III trials, while Veracyte remains on track to launch Prosigna LDT mid‑year and TrueMRD (MIBC) by the end of Q2. Interested in Veracyte, Inc.? Here are five stocks we like better. Veracyte (NASDAQ:VCYT) reported first-quarter 2026 results that management said marked an “excellent start” to the year, driven by double-digit growth in both revenue and test volume, improved profitability and progress toward two major product launches planned for later in 2026. Marc Stapley, Veracyte’s chief executive officer, said the quarter reflected “years of disciplined execution” that have made the company “a diversified, profitable company with a unique platform, multiple growth drivers, expanding clinical evidence, and strong clinician relationships.” → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Rebecca Chambers, Veracyte’s chief financial officer, said total revenue was $139.1 million, up 21% year-over-year, with total volume of approximately 47,600 tests, up 17% from the prior-year period. Testing revenue was $135.1 million, an increase of 26%, and testing volume was approximately 45,200 tests, up 19%. Chambers said testing average selling price (ASP) was $2,986, up 6% year-over-year and inclusive of approximately $4 million of prior period collections (PPCs). Excluding PPCs, normalized ASP increased 3% to $2,900, which she attributed to “continued strong collections.” → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches On profitability, Chambers said Veracyte delivered GAAP net income of $28.7 million. Adjusted EBITDA was $42.8 million, or 30.8% of revenue, which she said was “well above our long-term target of 25%.” Non-GAAP gross margin was 75.7%, up 350 basis points year-over-year, while non-GAAP operating expenses rose 7% to $64.6 million. The company generated $35.2 million of cash from operations and ended the quarter with $439.1 million in cash, cash equivalents and short-term inve...

Image source: The Motley Fool. May 5, 2026 Chief Executive Officer — Marc Stapley Chief Financial Officer — Rebecca Chambers Chief Commercial Officer — John Leite Chief Development and Technology Officer — Kevin Haas Chief Human Resources Officer — Tracy Ward VP, Investor Relations and Corporate Communications — Kelly Gura Need a quote from a Motley Fool analyst? Email [email protected] Kelly Gura: Good afternoon, everyone, and thank you for joining us today to review Veracyte, Inc.’s first quarter 2026 financial results. Joining me on the call are Marc Stapley, our Chief Executive Officer, and Rebecca Chambers, our Chief Financial Officer. John Leite, our Chief Commercial Officer, will also be available for Q&A. Earlier this afternoon, we issued a press release detailing our first quarter financial results, and we posted an accompanying presentation in the Investors section of our website. Before we begin, I would like to remind you that statements we make during this call will include forward-looking statements, as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties and the company can give no assurance they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte, Inc. files with the Securities and Exchange Commission, including the most recent Forms 10-Q and 10-K. In addition, this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included in today’s earnings release accessible from the Investors section of Veracyte, Inc.’s website. I am also pleased to highlight Veracyte, Inc.’s new website, which makes it easier to access information on our test portfolio, including a publication search tool to help navigate our extensive and growing clinical evidence base. I will now turn the call over to Marc Stapley, Veracyte, Inc.’s CEO. Marc Stapley: Thank you, Kelly, and thank you all for joining us today. We had an excellent start to 2026. In the first quarter, we delivered strong double-digit revenue and volume growth, exceeded our profitability expectations, and continued advanc...